Patient views: Genetic testing in mPC
Episode 8. Alicia Morgans and patient advocate Tony Collier discuss the impact of genetic testing in mPC, including how timing of testing and clinician-led conversations shape treatment decisions and emotional readiness. Collier shares his personal journey, emphasizing the importance of pre-test counseling and involving family members. “We just need to make sure we’re managing that man’s holistic needs properly and his family’s holistic needs and recognizing that those needs change as time goes by,” Collier notes. The episode explores how patient support groups empower self-advocacy and why access to testing is essential. Morgans explains how genetic testing can guide the use of targeted therapies, such as PARP inhibitors, offering personalized treatment options and hope for improved outcomes. View transcript.
Chapters
00:49 Genetic testing in the mPC journey
02:48 Timing of genetic testing in mPC
03:57 Genetic testing: Discussing results
05:29 Impact of patient advocacy groups
08:47 How to discuss results with family
13:14 Targeted therapies in mPC care
16:27 Patients on genetic testing in mPC
Meet the guest speaker
Tony Collier
Tony Collier is a patient representative and advocate for prostate cancer awareness and research in the UK. Diagnosed with advanced, incurable prostate cancer in 2017 and given a prognosis of 2 years, Collier has maintained stable health through treatment, supported by a dedicated exercise regimen. He supports a number of prostate cancer researchers with reviews of research grant applications, represents patients in the Prehab4Cancer program, and serves as Vice Chair of Tackle Prostate, a charity supporting over 140 UK support groups. He is also an ambassador, volunteer, awareness speaker, and fundraiser for Prostate Cancer UK. A former chartered accountant, Tony now works part-time in the profession while focusing on advocacy, family, and fundraising.
Disclosures: Previous work as a patient advocate with AstraZeneca, Bayer, MD Catapult, Medscape, and MSD.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.